MX336634B - Forma cristalina de un inhibidor de la interaccion de mdm2/4 y p53. - Google Patents
Forma cristalina de un inhibidor de la interaccion de mdm2/4 y p53.Info
- Publication number
- MX336634B MX336634B MX2013005631A MX2013005631A MX336634B MX 336634 B MX336634 B MX 336634B MX 2013005631 A MX2013005631 A MX 2013005631A MX 2013005631 A MX2013005631 A MX 2013005631A MX 336634 B MX336634 B MX 336634B
- Authority
- MX
- Mexico
- Prior art keywords
- mdm2
- interaction
- crystalline form
- inhibitor
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Una forma cristalina de la (S)-1-(4-cloro-fenil)-7-isopropoxi-6-me toxi-2-(4-{metil-[4-(4-metil-3-oxo-piperazin-1-iI)-trans-ciclohex il-metil]-amino}-fenil)-1, 4-dihidro-2H-isoquinolin-3-ona, la cual es útil en el tratamiento de una enfermedad o de un trastorno asociado con la interacción entre p53, o variantes de la misma, y MDM2 y/o MDM4, o variantes de las mismas, respectivamente, (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010078927 | 2010-11-19 | ||
| PCT/EP2011/070385 WO2012066095A1 (en) | 2010-11-19 | 2011-11-17 | Crystalline form of an inhibitor of mdm2/4 and p53 interaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005631A MX2013005631A (es) | 2013-07-05 |
| MX336634B true MX336634B (es) | 2016-01-26 |
Family
ID=45093718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005631A MX336634B (es) | 2010-11-19 | 2011-11-17 | Forma cristalina de un inhibidor de la interaccion de mdm2/4 y p53. |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US9073898B2 (es) |
| EP (1) | EP2640467B1 (es) |
| JP (1) | JP5667308B2 (es) |
| KR (1) | KR101561750B1 (es) |
| AR (1) | AR083905A1 (es) |
| AU (1) | AU2011331095B2 (es) |
| BR (1) | BR112013011966A2 (es) |
| CA (1) | CA2816810A1 (es) |
| CO (1) | CO6801719A2 (es) |
| CU (1) | CU24130B1 (es) |
| CY (1) | CY1116002T1 (es) |
| DK (1) | DK2640467T3 (es) |
| EC (1) | ECSP13012628A (es) |
| ES (1) | ES2528376T3 (es) |
| GT (1) | GT201300132A (es) |
| HK (1) | HK1184091A1 (es) |
| HR (1) | HRP20150231T1 (es) |
| IL (1) | IL226182A0 (es) |
| MA (1) | MA34666B1 (es) |
| ME (1) | ME02099B (es) |
| MX (1) | MX336634B (es) |
| MY (1) | MY160880A (es) |
| NZ (1) | NZ610296A (es) |
| PE (1) | PE20140420A1 (es) |
| PL (1) | PL2640467T3 (es) |
| PT (1) | PT2640467E (es) |
| RS (1) | RS53770B1 (es) |
| RU (1) | RU2013127661A (es) |
| SG (1) | SG190186A1 (es) |
| SI (1) | SI2640467T1 (es) |
| SM (1) | SMT201500059B (es) |
| TW (1) | TWI520950B (es) |
| WO (1) | WO2012066095A1 (es) |
| ZA (1) | ZA201303155B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008095063A1 (en) | 2007-01-31 | 2008-08-07 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| RU2582678C2 (ru) | 2010-08-13 | 2016-04-27 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
| TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
| US9408885B2 (en) * | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| WO2013123266A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| EA029312B1 (ru) | 2013-05-27 | 2018-03-30 | Новартис Аг | Производные имидазопирролидинона и их применение при лечении заболеваний |
| ES2656471T3 (es) | 2013-05-28 | 2018-02-27 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades |
| AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| US9550796B2 (en) | 2013-11-21 | 2017-01-24 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
| AU2014372167A1 (en) | 2013-12-23 | 2016-06-09 | Novartis Ag | Pharmaceutical combinations |
| KR20160100975A (ko) * | 2013-12-23 | 2016-08-24 | 노파르티스 아게 | 제약 조합물 |
| US10471120B2 (en) | 2014-09-24 | 2019-11-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| MX2017003819A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
| CN107614003A (zh) | 2015-03-20 | 2018-01-19 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| TWI804010B (zh) | 2015-08-03 | 2023-06-01 | 瑞士商諾華公司 | 作為血液學毒性生物標記之gdf-15 |
| JP2018528949A (ja) * | 2015-08-28 | 2018-10-04 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤およびｍｄｍ２阻害剤を使用する組み合わせ療法 |
| EP3340989B1 (en) | 2015-08-28 | 2023-08-16 | Novartis AG | Mdm2 inhibitors and combinations thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| KR101838687B1 (ko) | 2016-01-26 | 2018-03-15 | 한국생명공학연구원 | 나노포어를 이용한 단백질-단백질 상호작용 저해제 스크리닝 방법 |
| JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法 |
| CA3043004A1 (en) | 2016-11-15 | 2018-05-24 | Novartis Ag | Dose and regimen for hdm2-p53 interaction inhibitors |
| WO2018092064A1 (en) | 2016-11-18 | 2018-05-24 | Novartis Ag | Combinations of mdm2 inhibitors and bcl-xl inhibitors |
| JP2020510624A (ja) | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
| US11413284B2 (en) | 2017-09-12 | 2022-08-16 | Novartis Ag | Protein kinase C inhibitors for treatment of uveal melanoma |
| EP3694518A1 (en) | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3829420A (en) | 1970-07-13 | 1974-08-13 | Sumitomo Chemical Co | 3,4-dihydro-2(1h)-quinazolinones and preparation thereof |
| US4099002A (en) | 1970-12-23 | 1978-07-04 | Sumitomo Chemical Company, Limited | Quinazolinone derivatives and a process for production thereof |
| JPS4822715B1 (es) | 1970-12-28 | 1973-07-07 | ||
| JPS5427356B2 (es) | 1972-03-31 | 1979-09-10 | ||
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4258187A (en) | 1977-06-16 | 1981-03-24 | E. I. Du Pont De Nemours And Company | Process for preparing quinazolinone oxides |
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| DE3420799A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| RO119721B1 (ro) | 1992-10-28 | 2005-02-28 | Genentech Inc. | Antagonişti ai factorului de creştere al celulelor vasculare endoteliale |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE122005000053I2 (de) | 1995-03-30 | 2008-01-17 | Pfizer Prod Inc | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
| ES2249800T3 (es) | 1996-06-24 | 2006-04-01 | Pfizer Inc. | Derivados triciclicos sustituidos con fenilamino para el tratamento de enfermedades hiperproliferativas. |
| DE69738754D1 (de) | 1996-07-05 | 2008-07-17 | Cancer Rec Tech Ltd | Hemmer der interaktion zwischen p53 und mdm2 |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| EP0938597B1 (en) | 1996-09-06 | 2003-08-20 | Obducat Aktiebolag | Method for anisotropic etching of structures in conducting materials |
| DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
| WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CA2269118C (en) | 1996-11-18 | 2012-05-29 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| EP1058679B1 (en) | 1998-02-25 | 2005-10-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
| AU5620299A (en) | 1998-08-11 | 2000-03-06 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| KR20070087132A (ko) | 1998-11-20 | 2007-08-27 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법및 물질 |
| AU775806B2 (en) | 1998-12-22 | 2004-08-19 | Genentech Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
| JP4673977B2 (ja) | 1999-03-30 | 2011-04-20 | ノバルティス アーゲー | 炎症性疾患治療用フタラジン誘導体 |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| JP2001302515A (ja) | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2003062392A2 (en) | 2002-01-18 | 2003-07-31 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| WO2003095625A2 (en) | 2002-05-13 | 2003-11-20 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
| CA2536313A1 (en) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| PL1663185T3 (pl) | 2003-09-22 | 2009-06-30 | Onepharm Res & Development Gmbh | Zapobieganie i leczenie utraty kości wywołanej przez zapalenie i/lub za pośrednictwem układu odpornościowego |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| US20080153791A1 (en) | 2005-03-18 | 2008-06-26 | Onpharm Gmbh | 11Beta -Hydroxysteroid Dehydrogenases |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| WO2008034039A2 (en) | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
-
2010
- 2010-12-21 CU CU2012000098A patent/CU24130B1/es active IP Right Grant
-
2011
- 2011-11-17 JP JP2013539265A patent/JP5667308B2/ja not_active Expired - Fee Related
- 2011-11-17 PE PE2013001210A patent/PE20140420A1/es not_active Application Discontinuation
- 2011-11-17 BR BR112013011966A patent/BR112013011966A2/pt not_active IP Right Cessation
- 2011-11-17 PT PT11790916T patent/PT2640467E/pt unknown
- 2011-11-17 MY MYPI2013001567A patent/MY160880A/en unknown
- 2011-11-17 MX MX2013005631A patent/MX336634B/es unknown
- 2011-11-17 ES ES11790916.8T patent/ES2528376T3/es active Active
- 2011-11-17 SI SI201130417T patent/SI2640467T1/sl unknown
- 2011-11-17 NZ NZ610296A patent/NZ610296A/en not_active IP Right Cessation
- 2011-11-17 AU AU2011331095A patent/AU2011331095B2/en not_active Ceased
- 2011-11-17 KR KR1020137015727A patent/KR101561750B1/ko not_active IP Right Cessation
- 2011-11-17 AR ARP110104289A patent/AR083905A1/es unknown
- 2011-11-17 DK DK11790916.8T patent/DK2640467T3/en active
- 2011-11-17 ME MEP-2015-12A patent/ME02099B/me unknown
- 2011-11-17 PL PL11790916T patent/PL2640467T3/pl unknown
- 2011-11-17 CA CA2816810A patent/CA2816810A1/en not_active Abandoned
- 2011-11-17 US US13/988,227 patent/US9073898B2/en not_active Expired - Fee Related
- 2011-11-17 RS RS20150050A patent/RS53770B1/en unknown
- 2011-11-17 WO PCT/EP2011/070385 patent/WO2012066095A1/en active Application Filing
- 2011-11-17 RU RU2013127661/04A patent/RU2013127661A/ru not_active Application Discontinuation
- 2011-11-17 EP EP11790916.8A patent/EP2640467B1/en active Active
- 2011-11-17 US US13/298,351 patent/US8969351B2/en not_active Expired - Fee Related
- 2011-11-17 SG SG2013034988A patent/SG190186A1/en unknown
- 2011-11-18 TW TW100142392A patent/TWI520950B/zh not_active IP Right Cessation
-
2013
- 2013-04-30 ZA ZA2013/03155A patent/ZA201303155B/en unknown
- 2013-05-06 IL IL226182A patent/IL226182A0/en unknown
- 2013-05-14 MA MA35904A patent/MA34666B1/fr unknown
- 2013-05-17 EC ECSP13012628 patent/ECSP13012628A/es unknown
- 2013-05-17 GT GT201300132A patent/GT201300132A/es unknown
- 2013-05-24 CO CO13128275A patent/CO6801719A2/es not_active Application Discontinuation
- 2013-10-11 HK HK13111501.4A patent/HK1184091A1/xx not_active IP Right Cessation
-
2015
- 2015-02-12 CY CY20151100140T patent/CY1116002T1/el unknown
- 2015-02-27 HR HRP20150231AT patent/HRP20150231T1/hr unknown
- 2015-03-10 SM SM201500059T patent/SMT201500059B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX336634B (es) | Forma cristalina de un inhibidor de la interaccion de mdm2/4 y p53. | |
| CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
| MX2016001643A (es) | Articulo para el cuidado de heridas que presenta una superficie base sustancialmente poligonal o elipsoidal asi como al menos una escotadura dispuesta en un lado. | |
| ATE501210T1 (de) | Titandioxid enthaltendes komposit | |
| EP2232430A4 (en) | METHOD OF MANAGING MEDICAL PRODUCTS | |
| SI3034497T1 (sl) | 3,5-diamino-6-kloro-N-(N-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil )amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamid | |
| RS54457B1 (en) | CRYSTAL (R) - (E) -2- (4- (2- (5- (1- (3,5-Dichloropyridin-4-yl) ethoxy) -1H-indazol-3-yl) vinyl) -1H- PIRAZOL-1-IL) ETHANOL AND ITS USE AS FGFR INHIBITOR | |
| AR086913A1 (es) | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas | |
| IL177005A0 (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| CU20140060A7 (es) | 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato | |
| CR20140334A (es) | Forma galénica divisible que permite una liberación modificada del principio activo | |
| DE602008003911D1 (de) | Co-kristalle von propiconazol | |
| IN2013DN02552A (es) | ||
| HK1162494A1 (en) | Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine cdk | |
| EA028951B9 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| EP2845097A4 (en) | MODIFIED JVM WITH APPLICATION DOMAINS WITH MULTIPLE OWNERS AND MEMORY MANAGEMENT | |
| MX351608B (es) | Compensador de grosor de tejidos que comprende canales. | |
| UA107068C2 (xx) | Гербіцидна комбінація, що містить дифлуфенікан та інгібітор алс | |
| PL2240486T3 (pl) | Sole triazoliowe jako inhibitory PAR1, ich wytwarzanie i zastosowanie jako lek | |
| CL2013000492A1 (es) | Usos terapeuticos de 1-[2-(2,4-dimetil-fenilsulfanil) fenil]piperazina y sus sales para un tratamiento a largo plazo de una enfermedad del snc que esta asociado con un ligero o con un no aumento de peso | |
| TN2013000194A1 (en) | Crystalline form of an inhibitor of mdm 2/4 and p53 interaction | |
| CY1111328T1 (el) | Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα | |
| AR101523A1 (es) | Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1 | |
| EP2351285A4 (en) | USER AUTHENTICATION BASED ON CONTEXT, PROCESSING A WORKFLOW, AND DATA MANAGEMENT | |
| RS53014B (en) | 4R, 5S-ENANTIOMER 2- (5-METHYL-2-OXO-4-PHENYL-PYROLIDIN-1-IL) -ACETAMIDE WITH NOOTROPIC ACTIVITY |